Literature DB >> 12610802

A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis.

Jolanda Cibere1, Zhaozhi Deng, Yuanchang Lin, Runmei Ou, Yiting He, Zhiqiang Wang, Anona Thorne, Allen J Lehman, Ian K Tsang, John M Esdaile.   

Abstract

OBJECTIVE: To assess the efficacy of topical Tripterygium wilfordii (TW), a Chinese herbal therapy, in rheumatoid arthritis (RA).
METHODS: A 6 week randomized double blind placebo controlled study of 61 patients with RA meeting American College of Rheumatology (ACR) criteria was conducted in China. The primary outcome was a modified ACR-20 response rate, analyzed by logistic regression analysis.
RESULTS: The modified ACR-20 response rate differed significantly (topical TW 58% vs placebo 20%; p = 0.002). There was an 8.1-fold (95% CI 1.9-35.4) increase in the modified ACR-20 response for the TW compared to the placebo group, adjusted for age and erythrocyte sedimentation rate.
CONCLUSION: Topical TW appears efficacious for the treatment of RA, but larger studies are needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610802

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

Review 1.  Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases.

Authors:  Rui Han; Martin Rostami-Yazdi; Sascha Gerdes; Ulrich Mrowietz
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety.

Authors:  Jun Bao; Sheng-Ming Dai
Journal:  Rheumatol Int       Date:  2011-03-02       Impact factor: 2.631

3.  Triptolide induces anti-inflammatory cellular responses.

Authors:  Ranyia Matta; Xianxi Wang; Hui Ge; William Ray; Leif D Nelin; Yusen Liu
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

Review 4.  Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8).

Authors:  Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

5.  High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis.

Authors:  J Wang; Y Shan; Z Jiang; J Feng; C Li; L Ma; Y Jiang
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

6.  Suppression of ongoing experimental arthritis by a chinese herbal formula (huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation.

Authors:  Ying-Hua Yang; Rajesh Rajaiah; David Y-W Lee; Zhongze Ma; Hua Yu; Harry H S Fong; Lixing Lao; Brian M Berman; Kamal D Moudgil
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-19       Impact factor: 2.629

7.  Immunomodulation of Autoimmune Arthritis by Herbal CAM.

Authors:  Shivaprasad H Venkatesha; Rajesh Rajaiah; Brian M Berman; Kamal D Moudgil
Journal:  Evid Based Complement Alternat Med       Date:  2010-12-22       Impact factor: 2.629

8.  Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy.

Authors:  He-Ling Wen; Zhong-Shu Liang; Rui Zhang; Kan Yang
Journal:  Cardiovasc Diabetol       Date:  2013-03-25       Impact factor: 9.951

9.  The Inhibition of Spinal Astrocytic JAK2-STAT3 Pathway Activation Correlates with the Analgesic Effects of Triptolide in the Rat Neuropathic Pain Model.

Authors:  Jun Tang; Zhi-Hong Li; Shun-Nan Ge; Wei Wang; Xiao-Peng Mei; Wen Wang; Ting Zhang; Li-Xian Xu; Jin-Lian Li
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-29       Impact factor: 2.629

10.  Chinese Herbal Formula Huo-Luo-Xiao-Ling Dan Protects against Bone Damage in Adjuvant Arthritis by Modulating the Mediators of Bone Remodeling.

Authors:  Siddaraju M Nanjundaiah; David Y-W Lee; Brian M Berman; Kamal D Moudgil
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.